Sub-Q Bionics is developing a next-generation implantable lymphatic drainage system—described as bionic lymph node technology—intended to manage lymphedema by assisting lymphatic circulation beneath the skin. The technology is founded on scientific innovations from the Weizmann Institute of Science and Shamir Medical Center, and Yeda supported the company through its WIN venture creation platform. The company is headquartered in Stillwater, Minnesota. Its intended system aims to provide automatic fluid management and reduce symptoms such as pain, swelling, and mobility limitations for patients living with lymphedema. Sub-Q Bionics recently closed a $1.5 million pre-seed round to advance development toward pre-clinical milestones and to build regulatory and commercial plans. The company expects to open a seed round in Q2 2026.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2026